In colorectal cancer, epidermal growth factor receptor (EGFR) inhibitors like cetuximab and panitumumab are prescribed in RAS wild-type tumours, whereas angiogenesis is suppressed using VEGF inhibitors such as bevacizumab. This evidence concerns the gene EGFR and neoplasm.